The C-C motif chemokine receptor 8 (CCR8) is highly expressed in regulatory T cells. CCR8 is also expressed in many cancers and is associated with those progression. The development of monoclonal antibodies (mAbs) for CCR8 leads to cancer immunotherapy and elucidation of unknown mechanisms of CCR8-dependent cancer progression. In this study, we have developed an anti-mouse CCR8 (mCCR8) mAb (clone C8Mab-3, rat IgG1, kappa) using the Cell-Based Immunization and Screening (CBIS) method. We revealed that C8Mab-3 and its recombinant antibody (recC8Mab-3) bind to mCCR8-overexpressed Chinese hamster ovary (CHO)-K1 cells (CHO/mCCR8), but not to the parental CHO-K1 cells, in flow cytometry. In addition, C8Mab-3 and recC8Mab-3 reacted to P388 (a mouse lymphocyte-like cell) and J774-1 (a mouse macrophage-like cell), which express endogenous mCCR8. C8Mab-3 also detected exogenous and endogenous mCCR8 using immunocytochemistry. These results suggest that C8Mab-3, developed using the CBIS method, is useful for immunocytochemistry against exogenous and endogenous mCCR8.
Get full access to this article
View all access options for this article.
References
1.
ChensueSW, LukacsNW, YangTY, ShangX, FraitKA, KunkelSL, KungT, WiekowskiMT, HedrickJA, CookDN, ZingoniA, NarulaSK, ZlotnikA, BarratFJ, O'GarraA, NapolitanoM, and LiraSA: Aberrant in vivo T helper type 2 cell response and impaired eosinophil recruitment in CC chemokine receptor 8 knockout mice. J Exp Med, 2001; 193:573–584.
2.
FreemanCM, ChiuBC, StolbergVR, HuJ, ZeibecoglouK, LukacsNW, LiraSA, KunkelSL, and ChensueSW: CCR8 is expressed by antigen-elicited, IL-10-producing CD4+CD25+ T cells, which regulate Th2-mediated granuloma formation in mice. J Immunol, 2005; 174:1962–1970.
3.
InngjerdingenM, DamajB, and MaghazachiAA: Human NK cells express CC chemokine receptors 4 and 8 and respond to thymus and activation-regulated chemokine, macrophage-derived chemokine, and I-309. J Immunol, 2000; 164:4048–4054.
4.
InngjerdingenM, DamajB, and MaghazachiAA: Expression and regulation of chemokine receptors in human natural killer cells. Blood, 2001; 97:367–375.
5.
RoosRS, LoetscherM, LeglerDF, Clark-LewisI, BaggioliniM, and MoserB: Identification of CCR8, the receptor for the human CC chemokine I-309. J Biol Chem, 1997; 272:17251–17254.
6.
IslamSA, LingMF, LeungJ, ShrefflerWG, and LusterAD: Identification of human CCR8 as a CCL18 receptor. J Exp Med, 2013; 210:1889–1898.
7.
BiberK, ZuurmanMW, HomanH, and BoddekeHW: Expression of L-CCR in HEK 293 cells reveals functional responses to CCL2, CCL5, CCL7, and CCL8. J Leukoc Biol, 2003; 74:243–251.
8.
HowardOM, DongHF, ShirakawaAK, and OppenheimJJ: LEC induces chemotaxis and adhesion by interacting with CCR1 and CCR8. Blood, 2000; 96:840–845.
9.
StraslyM, DoronzoG, CappelloP, ValdembriD, AreseM, MitolaS, MooreP, AlessandriG, GiovarelliM, and BussolinoF: CCL16 activates an angiogenic program in vascular endothelial cells. Blood, 2004; 103:40–49.
10.
BarsheshetY, WildbaumG, LevyE, VitenshteinA, AkinseyeC, GriggsJ, LiraSA, and KarinN: CCR8(+)FOXp3(+) T(reg) cells as master drivers of immune regulation. Proc Natl Acad Sci USA, 2017; 114:6086–6091.
11.
KraehenbuehlL, WengCH, EghbaliS, WolchokJD, and MerghoubT: Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat Rev Clin Oncol, 2022; 19:37–50.
12.
WaldmanAD, FritzJM, and LenardoMJ: A guide to cancer immunotherapy: From T cell basic science to clinical practice. Nat Rev Immunol, 2020; 20:651–668.
13.
GalonJ, and BruniD: Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov, 2019; 18:197–218.
14.
KarinN: Chemokines in the landscape of cancer immunotherapy: How they and their receptors can be used to turn cold tumors into hot ones?. Cancers (Basel), 2021; 13:6317.
15.
EruslanovE, StoffsT, KimWJ, DaurkinI, GilbertSM, SuLM, ViewegJ, DaakaY, and KusmartsevS: Expansion of CCR8(+) inflammatory myeloid cells in cancer patients with urothelial and renal carcinomas. Clin Cancer Res, 2013; 19:1670–1680.
16.
VillarrealDO, L'HuillierA, ArmingtonS, MottersheadC, FilippovaEV, CoderBD, PetitRG, and PrinciottaMF: Targeting CCR8 induces protective antitumor immunity and enhances vaccine-induced responses in colon cancer. Cancer Res, 2018; 78:5340–5348.
17.
AsanoT, NanamiyaR, TakeiJ, NakamuraT, YanakaM, HosonoH, TanakaT, SanoM, KanekoMK, and KatoY: Development of anti-mouse CC chemokine receptor 3 monoclonal antibodies for flow cytometry. Monoclon Antib Immunodiagn Immunother, 2021; 40:107–112.
18.
NanamiyaR, TakeiJ, AsanoT, TanakaT, SanoM, NakamuraT, YanakaM, HosonoH, KanekoMK, and KatoY: Development of anti-human CC chemokine receptor 9 monoclonal antibodies for flow cytometry. Monoclon Antib Immunodiagn Immunother, 2021; 40:101–106.
19.
TanakaT, NanamiyaR, TakeiJ, NakamuraT, YanakaM, HosonoH, SanoM, AsanoT, KanekoMK, and KatoY: Development of anti-mouse CC chemokine receptor 8 monoclonal antibodies for flow cytometry. Monoclon Antib Immunodiagn Immunother, 2021; 40:65–70.
20.
YamadaS, ItaiS, NakamuraT, YanakaM, KanekoMK, and KatoY: Detection of high CD44 expression in oral cancers using the novel monoclonal antibody, C44Mab-5. Biochem Biophys Rep, 2018; 14:64–68.
21.
YamadaS, ItaiS, NakamuraT, YanakaM, ChangYW, SuzukiH, KanekoMK, and KatoY: Monoclonal antibody L1Mab-13 detected human PD-L1 in lung cancers. Monoclon Antib Immunodiagn Immunother, 2018; 37:110–115.
22.
TanakaT, AsanoT, SanoM, TakeiJ, HosonoH, NanamiyaR, NakamuraT, YanakaM, HaradaH, FukuiM, SuzukiH, UchidaK, NakagawaT, KatoY, and KanekoMK: Development of monoclonal antibody PMab-269 against California Sea Lion Podoplanin. Monoclon Antib Immunodiagn Immunother, 2021; 40:124–133.
23.
KanekoMK, SanoM, TakeiJ, AsanoT, SayamaY, HosonoH, KobayashiA, KonnaiS, and KatoY: Development and characterization of anti-sheep podoplanin monoclonal antibodies PMab-253 and PMab-260. Monoclon Antib Immunodiagn Immunother, 2020; 39:144–155.
24.
FurusawaY, KanekoMK, and KatoY: Establishment of C20Mab-11, a novel anti-CD20 monoclonal antibody, for the detection of B cells. Oncol Lett, 2020; 20:1961–1967.
25.
FurusawaY, KanekoMK, and KatoY: Establishment of an anti-CD20 monoclonal antibody (C20Mab-60) for immunohistochemical analyses. Monoclon Antib Immunodiagn Immunother, 2020; 39:112–116.
26.
ItaiS, FujiiY, NakamuraT, ChangYW, YanakaM, SaidohN, HandaS, SuzukiH, HaradaH, YamadaS, KanekoMK, and KatoY: Establishment of CMab-43, a sensitive and specific Anti-CD133 monoclonal antibody, for immunohistochemistry. Monoclon Antib Immunodiagn Immunother, 2017; 36:231–235.
27.
PlitasG, KonopackiC, WuK, BosPD, MorrowM, PutintsevaEV, ChudakovDM, and RudenskyAY: Regulatory T cells exhibit distinct features in human breast cancer. Immunity, 2016; 45:1122–1134.
28.
OhueY, and NishikawaH: Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?. Cancer Sci, 2019; 110:2080–2089.
29.
TanakaA, and SakaguchiS: Targeting Treg cells in cancer immunotherapy. Eur J Immunol, 2019; 49:1140–1146.
30.
TakeiJ, KanekoMK, OhishiT, HosonoH, NakamuraT, YanakaM, SanoM, AsanoT, SayamaY, KawadaM, HaradaH, and KatoY: A defucosylated antiCD44 monoclonal antibody 5mG2af exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma. Oncol Rep, 2020; 44:1949–1960.
31.
ItaiS, OhishiT, KanekoMK, YamadaS, AbeS, NakamuraT, YanakaM, ChangYW, OhbaSI, NishiokaY, KawadaM, HaradaH, and KatoY: Anti-podocalyxin antibody exerts antitumor effects via antibody-dependent cellular cytotoxicity in mouse xenograft models of oral squamous cell carcinoma. Oncotarget, 2018; 9:22480–22497.
32.
HosonoH, TakeiJ, OhishiT, SanoM, AsanoT, SayamaY, NakamuraT, YanakaM, KawadaM, HaradaH, KanekoMK, and KatoY: AntiEGFR monoclonal antibody 134mG2a exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma. Int J Mol Med, 2020; 46:1443–1452.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
